Ongoing Clinical Trials for Adenosquamous Cell Lung Cancer Stage IV
There are currently 3 clinical trials ongoing for advanced lung cancer, including stage IV adenosquamous cell lung cancer. These studies are testing new combinations of immunotherapy and chemotherapy treatments, as well as innovative diagnostic approaches. The trials are being conducted across several European countries including Germany, France, Spain, Hungary, and Czechia.
Clinical trial locations
- Czechia
- France
- Germany
- Hungary
- Spain
Study on Atezolizumab, Carboplatin, and Etoposide for Adults with Advanced Large-Cell Neuroendocrine Lung Cancer
This trial is testing a combination of immunotherapy and chemotherapy for patients with advanced large-cell neuroendocrine lung cancer, a serious type of lung cancer that grows and spreads quickly. The study aims to evaluate how well these treatments work together in improving patient survival.
Main inclusion criteria:
- Adults aged 18 years or older
- Confirmed diagnosis of locally advanced or metastatic large-cell neuroendocrine carcinoma without options for curative treatment
- No previous systemic therapy, or at least 6 months since completing curative treatment
- ECOG performance status of 0 to 2, meaning you can perform daily activities with some limitations
- Measurable disease according to standard criteria
- Adequate organ function, including liver, kidney, and blood cell counts within acceptable ranges
Main exclusion criteria:
- Recent cancer treatment within the last 4 weeks
- History of severe allergic reactions to the study drugs
- Active infections requiring treatment
- Pregnancy or breastfeeding
- Brain metastases unless treated and stable
- Active autoimmune diseases unless stable
- Recent drug or alcohol abuse within the last 12 months
Focus and goals: The study evaluates whether adding Atezolizumab, an immunotherapy drug that helps the immune system fight cancer, to standard chemotherapy can improve outcomes for patients. Treatment is given in cycles through intravenous infusion, with regular monitoring to assess response and manage side effects. The trial will continue until January 2029.
Investigational drugs: Atezolizumab is an immunotherapy that helps the immune system recognize and attack cancer cells. It is combined with platinum-based chemotherapy drugs (Carboplatin or Cisplatin) and Etoposide, which work by damaging cancer cell DNA to stop their growth and division.
Study on the Accuracy of OWL-EVO1 Test for Diagnosing Lung Cancer in Patients Eligible for Screening or with Suspicious CT Findings
This trial is studying a new diagnostic test called the OWL-EVO1 Breath Biopsy test. The goal is to assess how accurately this non-invasive test can identify lung cancer in people undergoing screening or who have suspicious findings on a CT scan.
Main inclusion criteria:
- Age between 45 and 85 years
- Ability to understand the study and provide informed consent
- Body mass index (BMI) between 16 and less than 40
- Had a CT scan of the chest within the last 6 months
Main exclusion criteria:
- Not eligible for lung cancer screening based on low dose CT scans
- No suspicious findings on CT scan that could indicate lung cancer
- Clinical presentations that do not include lung cancer as a possible diagnosis
Focus and goals: The study aims to determine if the OWL-EVO1 breath test can accurately differentiate between individuals with lung cancer and those without. Participants receive an infusion of a special solution and then provide breath samples at various timepoints. The test analyzes these samples to detect markers that may indicate cancer presence. The study monitors safety throughout and is expected to conclude by August 2024.
Investigational approach: OWL-EVO1 is a diagnostic test that works by analyzing breath samples to detect specific markers that may indicate the presence of lung cancer. The goal is to provide a non-invasive method for improving diagnostic accuracy in lung cancer screening.
Study on the Safety and Effects of ATL001 and Pembrolizumab in Adults with Advanced Non-Small Cell Lung Cancer
This trial explores a personalized cell therapy called ATL001, used alone or in combination with pembrolizumab, for treating advanced non-small cell lung cancer. The study aims to assess the safety and effectiveness of this innovative approach.
Main inclusion criteria:
- Age between 18 and 75 years at screening
- Life expectancy of at least 6 months
- Advanced non-small cell lung cancer that cannot be removed surgically or has spread
- Disease progression after standard treatments or inability to receive standard treatments due to side effects
- Measurable disease according to medical guidelines
- Good performance status (ECOG 0-1), meaning able to carry out daily activities with minimal limitations
- Previous treatment with a PD-1/PD-L1 inhibitor with disease progression or stable disease
- Adequate organ function based on blood test results
- Agreement to use effective birth control during and after treatment
Main exclusion criteria:
- Other types of cancer besides non-small cell lung cancer
- Certain medical conditions that might interfere with the study
- Taking medications that might interfere with the study
- Pregnancy or breastfeeding
- Recent participation in another clinical trial
- History of allergic reactions to the study drugs
Focus and goals: The study evaluates ATL001, a personalized therapy using specially designed T cells that target cancer cells. Patients undergo tissue collection, receive preparatory medications (lymphodepletion), and then receive ATL001 by infusion. Some patients also receive pembrolizumab in combination. Regular monitoring tracks tumor response and overall health outcomes. The study is expected to conclude by July 2027.
Investigational drugs: ATL001 is a cell therapy using modified immune cells (T cells) designed to recognize and attack cancer cells in patients with advanced non-small cell lung cancer. Pembrolizumab is an immunotherapy that blocks a protein called PD-1, helping the immune system attack cancer cells more effectively. The trial tests whether combining these two approaches improves treatment outcomes.
Summary
The three ongoing trials for stage IV adenosquamous cell lung cancer and related advanced lung cancers represent diverse approaches to improving treatment and diagnosis. Two trials focus on immunotherapy combinations: one testing atezolizumab with standard chemotherapy for large-cell neuroendocrine carcinoma in Germany, and another evaluating personalized cell therapy ATL001 with pembrolizumab across France, Spain, and Germany. The third trial, conducted in Hungary and Czechia, takes a different approach by testing a novel breath-based diagnostic test to improve early and accurate cancer detection.
These trials demonstrate growing interest in combining immunotherapy with either traditional chemotherapy or innovative personalized approaches. Most studies are in early to mid-phase stages, seeking to establish both safety and effectiveness. Germany appears as a key location with participation in multiple trials, while the geographical spread across Europe provides access opportunities for patients in several countries. All trials emphasize careful patient monitoring and require specific health criteria, particularly regarding organ function and performance status.
